Aptamer-Based Immunotheranostic Strategies
- 1 May 2023
- journal article
- research article
- Published by Mary Ann Liebert Inc in Cancer Biotherapy & Radiopharmaceuticals
- Vol. 38 (4), 246-255
- https://doi.org/10.1089/cbr.2022.0064
Abstract
The escape from immune surveillance is a hallmark of cancer progression. The classic immune checkpoint molecules PD-1, PD-L1, CTLA-4, LAG-3, TIM-3 novel ones are part of a sophisticated system of up- and downmodulation of the immune system, which is unregulated in cancer. In recent years, there have been remarkable advances in the development of targeting strategies, focused principally on immunotherapies aiming at blocking those molecules involved in the evasion of the immune system. However, there are still challenges to predicting their efficacy due to the wide heterogeneity of clinical responses. Thus, there is a need to develop new strategies, and theranostics has much to contribute in this field. Besides that, aptamers have emerged as promising molecules with the potential to generate a huge impact in the immunotheranostic field. They are single-stranded oligonucleotides with a unique self-folding tridimensional structure, with high affinity and specificity for the target. In particular, their small size and physicochemical characteristics make them a versatile tool for designing theranostic strategies. Here, we review the progress in theranostic strategies based on aptamers against immune checkpoints, and highlight the potential of those approaches.Keywords
This publication has 112 references indexed in Scilit:
- CD28 Aptamers as Powerful Immune Response ModulatorsMolecular Therapy Nucleic Acids, 2013
- Molecular Theranostics: A Primer for the Imaging ProfessionalAmerican Journal of Roentgenology, 2011
- Improved Survival with Ipilimumab in Patients with Metastatic MelanomaThe New England Journal of Medicine, 2010
- Conformational plasticity of RNA for target recognition as revealed by the 2.15 Å crystal structure of a human IgG–aptamer complexNucleic Acids Research, 2010
- Identification of an aptamer targeting hnRNP A1 by tissue slide‐based SELEXThe Journal of Pathology, 2009
- Assembling OX40 Aptamers on a Molecular Scaffold to Create a Receptor-Activating AptamerCell Chemical Biology, 2008
- Multivalent 4-1BB binding aptamers costimulate CD8+ T cells and inhibit tumor growth in miceJCI Insight, 2008
- CD28/B7 SYSTEM OF T CELL COSTIMULATIONAnnual Review of Immunology, 1996
- In vitro selection of RNA molecules that bind specific ligandsNature, 1990
- Systematic Evolution of Ligands by Exponential Enrichment: RNA Ligands to Bacteriophage T4 DNA PolymeraseScience, 1990